Exploring why, in fully outsourced clinical trial models, visibility across data systems can be less a technology question than a process one
Understanding where data signals can fall through the gaps when multiple CROs and vendors have their own internal processes, review cadences and timelines
Case study: a pharmacokinetic protocol deviation that never reached the sponsor because it fell between chairs in the communication chain
Case study: a screen failure cleaning exercise where a site misinterpretation of instructions led to an irreconcilable discrepancy
Exploring how stronger oversight frameworks and clearer agreement on what is expected, and from whom, could prevent these issues
Asking what we should be considering before adopting a new digital tool – recognising that a tool can integrate systems, but not always processes
What changes for sponsors when EHDS, eIDAS 2.0 wallets, the Data Governance Act and the AI Act converge on clinical trial data infrastructure.
Why current consent and audit-trail architectures will not survive a participant’s right to revoke or port their data, and what the Nordic region is already building as the working answer: consent evidence ledgers, privacy-preserving computation, and neutral data altruism intermediaries
Clinical supply uncertainty becomes manageable when supply considerations are introduced during protocol design and connected through a structured digital thread spanning planning, RTSM execution, and operational data
Endpoint demonstrates how closing the loop between forecasts and trial actuals enables teams to recognize change earlier, understand its implications faster, and act before it creates patient or study risk
